BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) shares were down 1.6% during trading on Monday . The stock traded as low as $2.34 and last traded at $2.51, with a volume of 100,763 shares traded. The stock had previously closed at $2.55.

Separately, Maxim Group restated a “buy” rating and set a $5.00 price target on shares of BrainStorm Cell Therapeutics in a research report on Saturday, June 4th.

The company’s market capitalization is $47.38 million. The stock’s 50-day moving average price is $2.39 and its 200-day moving average price is $2.41.

BrainStorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.15. Equities research analysts anticipate that BrainStorm Cell Therapeutics Inc. will post ($0.58) EPS for the current year.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.